|Composition : ||20mg|
|Indications : ||Remission indication in non lymphocytic leukemias, acute erythroid, leukemia, acute monocytic, leukemia, acute myelogenous leukemia, acute Lymphoblastic leukemia in children and adults. |
|Contraindications :||Pre- existing drug induced bone marrow supression, pre-existing heart disease, pregnancy. |
|Safety Profile : ||Cardiac, renal & hepatic functions adn serum uric levels should be evaluated prior to treatment. Completed blood count should be frequently monitored during the therapy extravasation at the site of injections may causes severe local tissue necrosis. |
|Adverse Effects :||Myelosuppression, myocardial toxicity, infants and children's are more susceptible to congestive heart failure (CHF), reversible alopecia gastrointestinal toxicity, acute nausea, vomiting, rare anaphylactoid reactions, hyperuricaemia, transient red urine. |
A special preparation as daunorubicin citrate liposome contain an equal amount of citrate encapsulated in lipid vesicles, formulated to maximize the selectivity of the drug for soiled tumors in sites.
|Drug Interactions :||1st line drug for advanced HIV associated keposi's saecoma.|
|Dosage :||Acute nonlymphocytic leukemia: Less than 60 years age -45 mg/m²/day i.v on days 1,2,3 on first course and on day 1&2 on subsequent course with cytosine.|
Acute Lymphocytic leukemia (All): Chlidren 25 mh/ m² i.v on day every week with prednisolone and vincristine.In < 2yrs of age: mg/kg dose in same manner Adult: 45 mg/m²per day i.v on drug 1,2,3 with vincristine., prednisolone and L-asparaginase.
In < 2yrs of age: mg/kg dose in same manner Adult: 45 mg/m²per day i.v on drug 1,2,3 with vincristine., prednisolone and L-asparaginase.
|Purity :||Not less than 99%.|